p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukaemia (Acute)
Conditions
Leukaemia (Acute), Leukaemia (Chronic), Leukaemia (Acute Myeloid), Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Promyelocytic)
Trial Timeline
Feb 1, 2011 → Feb 26, 2013
NCT ID
NCT01334060About p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine is a phase 2 stage product being developed by Inovio Pharmaceuticals for Leukaemia (Acute). The current trial status is completed. This product is registered under clinical trial identifier NCT01334060. Target conditions include Leukaemia (Acute), Leukaemia (Chronic), Leukaemia (Acute Myeloid).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01334060 | Phase 2 | Completed |
Competing Products
20 competing products in Leukaemia (Acute)